Zobrazeno 1 - 10 of 102 pro vyhledávání: '"Kathryn C. Arbour"'
1
Akademický článek
Phase 1 Clinical Trial of Trametinib and Ponatinib in Patients With NSCLC Harboring KRAS Mutations
Autor: Kathryn C. Arbour, MD, Eusebio Manchado, PhD, Matthew J. Bott, MD, Linda Ahn, NP, Yosef Tobi, BA, Andy Ai Ni, Helena A. Yu, MD, Alyssa Shannon, BA, Marc Ladanyi, MD, Victoria Perron, BS, Michelle S. Ginsberg, MD, Amanda Johnson, BA, Andrei Holodny, MD, Mark G. Kris, MD, Charles M. Rudin, MD, PhD, Piro Lito, MD, PhD, Neal Rosen, MD, PhD, Scott Lowe, PhD, Gregory J. Riely, MD, PhD
Publikováno v: JTO Clinical and Research Reports, Vol 3, Iss 1, Pp 100256- (2022)
Introduction: Somatic KRAS mutations occur in 25% of patients with NSCLC. Treatment with MEK inhibitor monotherapy has not been successful in clinical trials to date. Compensatory activation of FGFR1 was identified as a mechanism of trametinib resist
Externí odkaz: https://doaj.org/article/08ab67b4ab914fc8921cb36a60feebfe
Zobrazit plný text záznamu
2
Akademický článek
Concurrent Mutations in STK11 and KEAP1 Promote Ferroptosis Protection and SCD1 Dependence in Lung Cancer
Autor: Corrin A. Wohlhieter, Allison L. Richards, Fathema Uddin, Christopher H. Hulton, Àlvaro Quintanal-Villalonga, Axel Martin, Elisa de Stanchina, Umeshkumar Bhanot, Marina Asher, Nisargbhai S. Shah, Omar Hayatt, Darren J. Buonocore, Natasha Rekhtman, Ronglai Shen, Kathryn C. Arbour, Mark Donoghue, John T. Poirier, Triparna Sen, Charles M. Rudin
Publikováno v: Cell Reports, Vol 33, Iss 9, Pp 108444- (2020)
Summary: Concurrent loss-of-function mutations in STK11 and KEAP1 in lung adenocarcinoma (LUAD) are associated with aggressive tumor growth, resistance to available therapies, and early death. We investigated the effects of coordinate STK11 and KEAP1
Externí odkaz: https://doaj.org/article/79f1bb5015774d05860c9599ee982825
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje